Atopic dermatitis market is estimated to reach USD 12.9 Billion by 2025 and also to hit CAGR of 5.2% over the foremost time span. Atopic dermatitis can generally occur at any age but it was noticed that it is more likely to occur in childhood. The disease gets worse over time and can see clear fluid from the affected areas and it gets thick in some time. The early symptoms of this disease are itching, swollen and cracking skin and if treated well the severity goes down.
Key Market Dynamics:
- The increasing number of infectious diseases is certainly the main cause of the market to grow enormously. In addition, a rise in the consciousness towards health and to visit hospitals for diagnosis is surging the demand of the market. Growing prevalence for the high-quality treatment procedures from the public is influencing the growth of the Atopic dermatitis market towards positive.
- However, the cost for installation and maintenance of the equipment in the laboratories are slightly hampering the growth of the market. Also, lack of complete knowledge over the disease especially in rural areas is inhibiting the growth of the market. The rise in the complications with the treatment procedures and increasing side effects issues have remained a challenging factor for the market.
- Growth opportunities for the Atopic Dermatitis Market lie in the ongoing research to ensure quality drugs in the biotechnology field. Furthermore, the market is accelerated by growing prevalence for the launch of reimbursement schemes by the government in favor of the end-users. Increasing incidences of food allergies are also one of the factors bolstering the growth of the market.
Calcitonin segment is leading with the highest shares of the market
On the basis of type, the market is segmented into calcitonin, interferon, monoclonal antibodies, erythropoietin and hormone among others. Calcitonin segment is witnessed to lead the highest shares of the market. Increasing capital income in developed and developing countries is fueling the demand of the market.
By application, the infectious disease market is to have dominant shares in the forecast period
On the basis of applications, the market is divided into infectious diseases, chronic diseases, blood disorders, and others. Infectious diseases are accounted to have highest shares from the past decade. Increasing incidences of atopic dermatitis incidences are mainly promoting the demand of the market.
Hospitals are gaining traction to hold the largest shares of the market
By end-users, the market segments are research centers, clinics, and hospitals. Research centers are expected to register the highest CAGR by 2022. Increasing support the public and private organizations is magnifying the growth of the market.
North America predicted to lead
Regionally, the Atopic dermatitis market is divided into Asia Pacific, North America, Europe, and Middle East & Africa. North America is holding the significant shares of the market from the recent years and estimated to continue the same growth in the foreseen years by owing to adoption of the latest technological developments and launch of various innovative systems for the medical sector. Europe is next to North America in holding the dominant shares of the market. The rise in the investments on the research institutes by public and private organizations are lavishing the demand of the Atopic dermatitis market in this region. The Asia Pacific is accounted to have huge growth opportunities in the near future with the rising populations and also increasing the scale of the hospitals. The Middle East and Africa are inclined to have the fastest growth rate in the coming years. Growing awareness of the treatment procedures for infectious diseases is setting up demand for the market.
The players involved in the atopic dermatitis market are Allergan Plc. (Republic of Ireland), Galderma S.A. (Switzerland), Pfizer Inc. (U.S.), Meda Pharmaceuticals (U.S.), Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Anacor Pharmaceuticals Inc. (U.S.), Valeant Pharmaceuticals International Inc (Canada), Regeneron Pharmaceuticals Inc. (U.S.), Sanofi S.A. (France) and Astellas Pharma Inc. (Japan) among others.
The Research Report segments the Global Atopic Dermatitis Market into the following submarkets:
Atopic Dermatitis Market Analysis - By Disease Severity:
Atopic Dermatitis Market Analysis - By Treatment Type:
- Corticosteroids
- Antihistamines
- Calcineurin Inhibitors
- Immunomodulators
- Biologic Therapy
- PDE-4 Inhibitor
- Antibiotics
- Moisturizers/Emollients
- Off-Label Therapies
Atopic Dermatitis Market Analysis - By Distribution Channel:
- Hospitals
- Dermatology Clinics
- Retail Pharmacy
- Online Pharmacy
Atopic Dermatitis Market Analysis - By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Request Sample Brochure for TOC
+1 888 709 8757
Chat With Us